Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation?

An excess of reactive carbonyl compounds (carbonyl stress) and their reaction products, advanced glycation endproducts (AGEs), are thought to play a decisive role in the pathogenesis of neurodegenerative disorders and Parkinson's disease (PD) in particular. Accumulation of AGEs in various intracellular pathological hallmarks of PD, such as Lewy bodies, densely crosslinked intracellular protein deposits formed from neurofilament components and alpha-synuclein, have already been described in patients in advanced stages of the disease. There is, however, no indication of the involvement of AGE-induced crosslinking of alpha-synuclein in very early stages of the disease. In this study, we observed that AGEs and alpha-synuclein are similarly distributed in very early Lewy bodies in the human brain in cases with incidental Lewy body disease. These cases might be viewed as pre-Parkinson patients, i.e. patients who came for autopsy before the possible development of clinical signs of PD. AGEs are both markers of transition metal induced oxidative stress as well as, inducers of protein crosslinking and free radical formation by chemical and cellular processes. Thus, it is likely that AGE promoted formation of Lewy bodies reflects very early causative changes rather than late epiphenomenons of PD.

[1]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[2]  P. Riederer,et al.  High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expression , 1999 .

[3]  P. Riederer,et al.  Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts , 1998, Journal of Neural Transmission.

[4]  G. Perry,et al.  Sequestration of iron by Lewy bodies in Parkinson’s disease , 2000, Acta Neuropathologica.

[5]  R. Khalifah,et al.  Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.

[6]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[7]  B. Hyman,et al.  α-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining , 2000, Acta Neuropathologica.

[8]  G. Perry,et al.  Early contribution of oxidative glycation in Alzheimer disease , 1996, Neuroscience Letters.

[9]  Paul J Thornalley Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. , 1998, Chemico-biological interactions.

[10]  E. Braak,et al.  Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease , 1998, Brain Research.

[11]  R. Krüger,et al.  Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders , 2000, Journal of neural transmission.

[12]  P. Riederer,et al.  The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[13]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[14]  M. Smith,et al.  Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease , 1996, Brain Research.

[15]  G. Münch,et al.  Distribution of advanced glycation end products in the cerebellar neurons of dogs , 1998, Brain Research.

[16]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[17]  J. Eaton,et al.  Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. , 1998, Biochemical and biophysical research communications.

[18]  M. Brownlee,et al.  Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. , 1990, Biochemical and biophysical research communications.

[19]  P Riederer,et al.  Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress? , 1998, Annals of neurology.

[20]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[21]  P. Riederer,et al.  Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. , 2000, European journal of biochemistry.

[22]  J. Thome,et al.  Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.

[23]  P. Riederer,et al.  Understanding Parkinson's disease. , 1997, Scientific American.

[24]  P. Riederer,et al.  Parkinson's disease: a major hypokinetic basal ganglia disorder , 1999, Journal of Neural Transmission.

[25]  H. Braak,et al.  Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.